Home LiteratureArticle Details
PMID: 21966373 Published · ppublish English Journal Article

Neuropathology in mice expressing mouse alpha-synuclein.

PloS one ·Vol. 6 ·No. 9 ·2011-00-00 ·Pages e24834

Rieker C, Dev KK, Lehnhoff K, Barbieri S, Ksiazek I, Kauffmann S, Danner S, Schell H, Boden C, Ruegg MA, Kahle PJ, van der Putten H, Shimshek DR

Abstract

α-Synuclein (αSN) in human is tightly linked both neuropathologically and genetically to Parkinson's disease (PD) and related disorders. Disease-causing properties in vivo of the wildtype mouse ortholog (mαSN), which carries a threonine at position 53 like the A53T human mutant version that is genetically linked to PD, were never reported. To this end we generated mouse lines that express mαSN in central neurons at levels reaching up to six-fold compared to endogenous mαSN. Unlike transgenic mice expressing human wildtype or mutant forms of αSN, these mαSN transgenic mice showed pronounced ubiquitin immunopathology in spinal cord and brainstem. Isoelectric separation of mαSN species revealed multiple isoforms including two Ser129-phosphorylated species in the most severely affected brain regions. Neuronal Ser129-phosphorylated αSN occurred in granular and small fibrillar aggregates and pathological staining patterns in neurites occasionally revealed a striking ladder of small alternating segments staining either for Ser129-phosphorylated αSN or ubiquitin but not both. Axonal degeneration in long white matter tracts of the spinal cord, with breakdown of myelin sheaths and degeneration of neuromuscular junctions with loss of integrity of the presynaptic neurofilament network in mαSN transgenic mice, was similar to what we have reported for mice expressing human αSN wildtype or mutant forms. In hippocampal neurons, the mαSN protein accumulated and was phosphorylated but these neurons showed no ubiquitin immunopathology. In contrast to the early-onset motor abnormalities and muscle weakness observed in mice expressing human αSN, mαSN transgenic mice displayed only end-stage phenotypic alterations that manifested alongside with neuropathology. Altogether these findings show that increased levels of wildtype mαSN does not induce early-onset behavior changes, but drives end-stage pathophysiological changes in murine neurons that are strikingly similar to those evoked by expression of human wildtype or mutant forms.

MeSH Terms
Animals Axons/metabolism,pathology,ultrastructure Blotting, Western Brain/metabolism,pathology,physiopathology Female Gene Expression Hippocampus/metabolism,pathology,physiopathology Humans Immunohistochemistry In Situ Hybridization Male Maze Learning/physiology Mice Mice, Inbred C57BL Mice, Knockout Mice, Transgenic Microscopy, Immunoelectron Motor Activity/physiology Nervous System Diseases/genetics,metabolism,physiopathology Neuromuscular Junction/metabolism,pathology,physiopathology Neurons/metabolism,pathology,ultrastructure Phosphorylation Spinal Cord/metabolism,pathology,physiopathology Ubiquitin/metabolism alpha-Synuclein/genetics,metabolism
Chemicals
Ubiquitin alpha-Synuclein
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Rieker Claus
Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
Dev Kumlesh K
Lehnhoff Katja
Barbieri Samuel
Ksiazek Iwona
Kauffmann Sabine
Danner Simone
Schell Heinrich
Boden Cindy
Ruegg Markus A
Kahle Philipp J
van der Putten Herman
Shimshek Derya R
References (33)
33 references, click to expand
  1. Neuropathology in mice expressing human alpha-synuclein.
    J Neurosci. 2000 Aug 15;20(16):6021-9 PMID: 10934251
  2. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Science. 2000 Feb 18;287(5456):1265-9 PMID: 10678833
  3. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain.
    J Neurosci. 2000 Sep 1;20(17):6365-73 PMID: 10964942
  4. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    J Neurosci. 2002 Apr 1;22(7):2780-91 PMID: 11923443
  5. Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment.
    Lab Invest. 1998 Sep;78(9):1169-77 PMID: 9759660
  6. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations.
    J Neural Transm Suppl. 2000;(58):53-63 PMID: 11128613
  7. Genetic animal models of Parkinson's disease.
    Neuron. 2010 Jun 10;66(5):646-61 PMID: 20547124
  8. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded.
    Biochemistry. 1996 Oct 29;35(43):13709-15 PMID: 8901511
  9. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
    J Neurochem. 2009 Jul;110(1):208-19 PMID: 19457126
  10. Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies.
    J Clin Invest. 2002 Nov;110(10):1429-39 PMID: 12438441
  11. alpha-Synuclein is phosphorylated in synucleinopathy lesions.
    Nat Cell Biol. 2002 Feb;4(2):160-4 PMID: 11813001
  12. Endogenous serine protease inhibitor modulates epileptic activity and hippocampal long-term potentiation.
    J Neurosci. 1997 Jun 15;17(12):4688-99 PMID: 9169529
  13. Part I: parkin-associated proteins and Parkinson's disease.
    Neuropharmacology. 2003 Jul;45(1):1-13 PMID: 12814656
  14. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.
    EMBO Rep. 2002 Jun;3(6):583-8 PMID: 12034752
  15. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis.
    J Biol Chem. 2000 Nov 3;275(44):34393-8 PMID: 10952980
  16. Improvement of the solubilization of proteins in two-dimensional electrophoresis with immobilized pH gradients.
    Electrophoresis. 1997 Mar-Apr;18(3-4):307-16 PMID: 9150907
  17. Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
    Neuropharmacology. 2003 Jul;45(1):14-44 PMID: 12814657
  18. An immunoblotting method for high-resolution isoelectric focusing of protein isoforms on immobilized pH gradients.
    Electrophoresis. 2001 Jun;22(10):1887-93 PMID: 11465484
  19. Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra.
    Hum Gene Ther. 2002 Mar 20;13(5):605-12 PMID: 11916484
  20. Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.
    Am J Pathol. 2001 Dec;159(6):2215-25 PMID: 11733371
  21. Neurofibrillary tangles in the dentate granule cells of patients with Alzheimer's disease, Lewy body disease and progressive supranuclear palsy.
    Acta Neuropathol. 1997 Jan;93(1):7-12 PMID: 9006651
  22. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred.
    Acta Neuropathol. 2002 Jul;104(1):7-11 PMID: 12070658
  23. Alpha-synuclein in Lewy bodies.
    Nature. 1997 Aug 28;388(6645):839-40 PMID: 9278044
  24. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies.
    Am J Pathol. 2003 Jul;163(1):91-100 PMID: 12819014
  25. Clinical and neuropathological correlates of dementia with Lewy bodies.
    Ann N Y Acad Sci. 2000;920:9-15 PMID: 11193181
  26. Neuropathology of Parkinson's disease.
    J Neuropathol Exp Neurol. 1996 Mar;55(3):259-72 PMID: 8786384
  27. Molecular and clinical prodrome of Parkinson disease: implications for treatment.
    Nat Rev Neurol. 2010 Jun;6(6):309-17 PMID: 20479780
  28. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.
    Neuron. 2002 May 16;34(4):521-33 PMID: 12062037
  29. [Neuroanatomy of Parkinson disease. Changes in the neuronal cytoskeleton of a few disease-susceptible types of neurons lead to progressive destruction of circumscribed areas in the limbic and motor systems].
    Nervenarzt. 2000 Jun;71(6):459-69 PMID: 10919140
  30. Establishment of a first-order kinetic model of light chain-associated amyloid fibril extension in vitro.
    Biochim Biophys Acta. 2002 Nov 19;1601(1):110-20 PMID: 12429509
  31. alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining.
    Acta Neuropathol. 2000 Apr;99(4):352-7 PMID: 10787032
  32. Pattern of brain destruction in Parkinson's and Alzheimer's diseases.
    J Neural Transm (Vienna). 1996;103(4):455-90 PMID: 9617789
  33. Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions.
    J Biol Chem. 2002 Dec 13;277(50):49071-6 PMID: 12377775
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2011-00-00
Epub
2011-00-26
Pages
e24834
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC3180287
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com